Jul 5, 2023 9:00 am EDT Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
May 17, 2023 9:00 am EDT Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference
May 8, 2023 7:00 am EDT Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
Apr 4, 2023 8:01 am EDT Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
Mar 13, 2023 8:00 am EDT Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
Mar 8, 2023 9:00 am EST Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference